PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Scott J. Rodig et al.|Blood|2019Cited by 187
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|The Lancet Haematology|2019Cited by 72
A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphomaPhilippe Armand, Eric D. Jacobsen, Robert Redd et al.|British Journal of Haematology|2016Cited by 68
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J. Frigault, Robin Joyce, Philippe Armand et al.|Blood Advances|2020Cited by 65
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W. Merryman, Eric D. Jacobsen, Natasha Edwin et al.|Blood Advances|2020Cited by 58